PA007617.m1:In Vivo Grade Recombinant Anti-human CA19-9 Monoclonal Antibody (Clone: 1116-NS-19-9), Mouse IgG1 Kappa
Recombinant Mouse IgG1 Monoclonal Antibody.
Clone: 1116-NS-19-9.
Isotype: Mouse IgG1 Kappa.
Source:The anti-human CA19-9 monoclonal antibody (clone: 1116-NS-19-9) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 1116-NS-19-9) specifically binds to human CA19-9.
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CA19-9 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human CA19-9 monoclonal antibody of clone 1116-NS-19-9 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-human CA19-9 antibody (Clone: 1116-NS-19-9):
Differential expression of CD175 and CA19-9 in pancreatic adenocarcinoma
Kozak, R. P., et al. Sci Rep. 2024 Feb 3;14(1):2698. doi: 10.1038/s41598-024-52698-8. PMID: 38307988
The 1116-NS-19-9 antibody detected CA19-9 in pancreatic ductal adenocarcinoma (PDAC) samples via semi-quantitative IHC, showing heterogeneous expression with variable intensity in ductal structures. CD175, consistently positive in tumor cells, was identified as a potential complementary biomarker to CA19-9, which was co-detected with HECA-452 for CD15s.
Tags: anti-human CA19-9 1116-NS-19-9; anti-human CA19-9 1116-NS-19-9 mAb
Tumor‐Associated Carbohydrate Antigen 19–9 (CA 19–9), a Promising Target for Antibody‐Based Detection, Diagnosis, and Immunotherapy of Cancer
Nakisa, M., et al. ChemMedChem. 2024 Nov 7;e202400491. doi: 10.1002/cmdc.202400491. PMID: 39482752
The 1116-NS-19-9 monoclonal antibody identified CA19-9 in 1979, with a constructed scFv (RA9-23) showing stronger binding to WiDr and Capan-2 cell lines than the native antibody. Increased CA19-9 expression promoted tumor metastasis via E-selectin binding, and in mice, it caused severe pancreatitis through EGFR signaling hyperactivation.
Tags: anti-human CA19-9 1116-NS-19-9 antibody in vivo; anti-human CA19-9 1116-NS-19-9 in animal model
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Duffy, M. J., et al. World J Gastrointest Surg. 2020 Dec 27;12(12):468-481. doi: 10.4240/wjgs.v12.i12.468. PMID: 33352866
CA19-9, first identified in 1979 by the 1116-NS-19-9 antibody in the SW1116 colorectal carcinoma cell line, is a sialylated Lewis^a^ antigen associated with pancreatic ductal adenocarcinoma (PDAC). Its utility spans serum, saliva, pancreatic cysts, and immunohistochemical applications, reflecting its role as a key tumor marker in PDAC.
Tags: anti-human CA19-9 1116-NS-19-9 mAb in animal model; anti-human CA19-9 1116-NS-19-9 in cancer research
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal
Ballehaninna, U. K., et al. J Gastrointest Oncol. 2012 Jun 1;3(2):105-119. doi: 10.3978/j.issn.2078-6891.2012.024. PMID: 22811875
CA19-9, identified by the 1116-NS-19-9 antibody in the SW1116 colorectal cancer cell line, is a key tumor marker for pancreatic cancer. A comprehensive review (1979–2010) evaluated its role in diagnosis, prognosis, and management, highlighting its utility despite the exploration of additional markers from serum, pancreatic tissue, and other fluids.
Tags: anti-human CA19-9 1116-NS-19-9 mAb in cancer research; anti-human CA19-9 (1116-NS-19-9) in vivo antibody
CA 19-9 and Pancreatic Cancer
Ballehaninna, U. K., et al. Gastroenterol Res Pract. 2013;2013:710836. doi: 10.1155/2013/710836. PMID: 23592950
CA19-9, a sialylated Lewis^a^ antigen identified by the 1116-NS-19-9 antibody in the SW1116 colorectal carcinoma cell line in 1979, is a component of glycoproteins and mucins. Its concentration, measured by ELISA, aids in detecting pancreatic cancer early, potentially improving prognosis through curative resection.
Tags: anti-CA19-9 clone 1116-NS-19-9; clone 1116-NS-19-9 of anti-human CA19-9 mAb
For more references about anti-human CA19-9 antibody (1116-NS-19-9), please contact our scientific support team with message@sydlabs.com.